23 February 2024 - The EMA has recommended granting a marketing authorisation in the European Union for a new therapy for the treatment of adult patients with amyotrophic lateral sclerosis, a rare and often fatal disease that causes muscles to become weak and leads to paralysis. 

Qalsody (tofersen) is indicated for the treatment of adults with amyotrophic lateral sclerosis, who have a mutation in the superoxide dismutase 1 gene.

Read EMA press release